


Correction: Dual neutralisation of interleukin-17A and interleukin-17F with bimekizumab in patients with active ankylosing spondylitis: results from a 48-week phase IIb, randomised, double blind, placebo-controlled, dose-ranging study

Van der Heijde D, Gensler LS, Deodhar, *et al.* Dual neutralisation of interleukin-17A and interleukin-17F with bimekizumab in patients with active ankylosing spondylitis: results from a 48-week phase IIb, randomised, double blind, placebo-controlled, dose-ranging study. *Ann of Rheum Dis* 2020;79:595–4.



The legend for the Figure 1B,C labels should read 'Placebo/BKZ 320 mg; n=36' instead of 'Placebo/BKZ 160 mg; n=36'; and 'BKZ 320 mg; n=61 (FAS); n=61 (DBS)' instead of 'BKZ 160 mg; n=61 (FAS); n=61 (DBS)'.

A citation to the following paper should be included after first mention of the copyrighted SPARCC instrument: Maksymowych WP, *et al.* Spondyloarthritis Research Consortium of Canada MRI index for assessment of sacroiliac joint inflammation in ankylosing spondylitis. *Arthritis Rheum* 2005;53(5):703–9. doi: 10.1002/art.21445.



OPEN ACCESS

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Ann Rheum Dis 2020;**79**:e121. doi:10.1136/annrheumdis-2020-216980corr1

